Nemaura Medical Inc. (NMRD): Price and Financial Metrics


Nemaura Medical Inc. (NMRD): $9.65

-0.92 (-8.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NMRD Stock Price Chart Interactive Chart >

Price chart for NMRD

NMRD Price/Volume Stats

Current price $9.65 52-week high $17.40
Prev. close $10.57 52-week low $3.12
Day low $9.34 Volume 565,500
Day high $10.82 Avg. volume 1,153,042
50-day MA $9.69 Dividend yield N/A
200-day MA $6.24 Market Cap 221.27M

Nemaura Medical Inc. (NMRD) Company Bio


Nemaura Medical Inc. designs and develops proprietary drug delivery platforms. The Company produces therapeutic delivery systems including patches and injectors. Nemaura Medical offers its products to the pharmaceutical and healthcare industries.


NMRD Latest News Stream


Event/Time News Detail
Loading, please wait...

NMRD Latest Social Stream


Loading social stream, please wait...

View Full NMRD Social Stream

Latest NMRD News From Around the Web

Below are the latest news stories about Nemaura Medical Inc that investors may wish to consider to help them evaluate NMRD as an investment opportunity.

Nemaura Medical to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Loughborough, England, June 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021. Dr. Chowdhury will deliver his corporate presentation on June 9 at 1:00pm ET, Track 3. Investors can register to watch the presentation here. Investors interested in scheduling a meeting with management should contact [email protected] About Nemaura Medical, Inc. Nemaura Medical Inc. is a medical technology company developing and comme...

Yahoo | June 1, 2021

35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021

RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Summer Solstice - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, June 1, 2021, with company presentations beginning at 9am Eastern Time.

Yahoo | May 27, 2021

Neumaura Medical, Inc. to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021

Loughborough, England, May 26, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021. Chief Executive Officer Faz Chowdhury, Ph.D. will deliver his corporate presentation on June 2, 2021 at 4:00pm ET. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2134/41524 To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected]

Yahoo | May 26, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's Friday and we're kicking it off right with a look at the biggest pre-market stock movers for the last day of trading this week!

William White on InvestorPlace | May 21, 2021

Nemaura Medical Announces Progress on Listing of sugarBEAT® For Reimbursement in Germany

Loughborough, England, May 06, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced progress with the German regulatory authority (GBA) to achieve reimbursement for its sugarBEAT® device. After initial review, the GBA has determined that sugarBEAT does not require GBA review and will go directly to the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) for a listing on the durable medical catalog. The Company is now completing the application for this listing, which is expected to be faster than where a GBA review is required. “The availabi...

Yahoo | May 6, 2021

Read More 'NMRD' Stories Here

NMRD Price Returns

1-mo -18.84%
3-mo 20.32%
6-mo 120.82%
1-year -34.93%
3-year -64.13%
5-year N/A
YTD 155.97%
2020 7.71%
2019 -61.11%
2018 -82.35%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7604 seconds.